HAVCR2 and neoplasm: Treatment of anti-TIM-3 antibody reduced tumor size, which was associated with increased tumor-infiltrating CD8+ T cells owing to decreased apoptosis of TIM-3+ CD8+ T cells (Fig. 5g).